IDEXX Laboratories, Inc. (IDXX)
| Market Cap | 44.95B +39.2% |
| Revenue (ttm) | 4.30B +10.4% |
| Net Income | 1.06B +19.3% |
| EPS | 13.08 +22.6% |
| Shares Out | 79.42M |
| PE Ratio | 43.27 |
| Forward PE | 38.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 598,170 |
| Open | 556.92 |
| Previous Close | 560.93 |
| Day's Range | 552.00 - 567.94 |
| 52-Week Range | 424.48 - 769.98 |
| Beta | 1.72 |
| Analysts | Buy |
| Price Target | 706.00 (+24.75%) |
| Earnings Date | May 5, 2026 |
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price target is $706.0, which is an increase of 24.75% from the latest price.
News
IDEXX Laboratories to Release 2026 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tues...
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference
A robust innovation-driven strategy is fueling double-digit growth in veterinary diagnostics, supported by expanding international markets, increased pet longevity, and accelerated investment in new p...
IDEXX Laboratories Transcript: BofA Securities Animal Health Summit
Double-digit organic revenue growth and record instrument placements were achieved in 2025, driven by innovation in diagnostic platforms like inVue Dx and Cancer Dx. Despite sector headwinds, recurrin...
IDEXX Laboratories to Present at Two Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 26, 9:55 am –...
IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results
IDEXX Laboratories Inc. (NASDAQ: IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.
IDEXX Laboratories Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw double-digit organic revenue growth, record instrument placements, and strong EPS gains, driven by innovation and international expansion. 2026 guidance anticipates continued...
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
Animal diagnostics maker IDEXX Laboratories on Monday forecast 2026 revenue and profit above Wall Street estimates, betting that resilient demand at veterinary clinics and higher testing per visit wil...
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. Fourth Quarter and Full ...
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
WESTBROOK, Maine--(BUSINESS WIRE)--ImageVue DR50 Plus introduces high-definition diagnostic imaging at the lowest dose of radiation, accelerating diagnosis and improving staff safety.
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
WESTBROOK, Maine--(BUSINESS WIRE)--Cancer Dx Panel expansion and inVue Dx FNA cytology rollout advance veterinary cancer care, enabling comprehensive mast cell tumor testing for dogs.
IDEXX Announces CEO Succession
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President an...
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial r...
Final Trades: Palo Alto Networks, Capital One, Idexx Labs and the XLB
CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may b...
Final Trades: Meta, S&P Global and Idexx Lab
The Investment Committee give you their top stocks to watch for the second half.
Idexx Stock Pops on Earnings. Pet Health Is Booming.
Vet visits are down, but growing revenue per visit is more than making up for it, the company says.
Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook
IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) stock is trading higher on Monday after it reported better-than-expected third-quarter financial results and raised its 2025 forecast.
IDEXX Laboratories Earnings Call Transcript: Q3 2025
Q3 delivered double-digit revenue and EPS growth, driven by strong CAG Diagnostics performance, robust instrument placements, and innovation in products like MUDX and CancerDx. Full-year guidance was ...
IDEXX raises annual forecasts as pet owners spend more on preventive care
IDEXX Laboratories raised its full-year profit and revenue forecasts on Monday after reporting better third-quarter results than last year, as the pet diagnostics maker banks on owners spending more o...
IDEXX Laboratories Announces Third Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company repor...
IDEXX Laboratories Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.
IDEXX Laboratories to Release 2025 Third Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Mond...
IDEXX Laboratories Elects Karen Peacock to Board of Directors
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Direct...
IDEXX Laboratories Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Diagnostics remain central to veterinary practice, with growth driven by innovation, global expansion, and recurring revenue streams. The company targets 10%+ organic revenue and 15%+ EPS growth, supp...